Latest news
Patient-derived organoids reveal which breast tumors may resist standard therapies - Medical XpressMedical Xpress · Mon, 10 Aug 2026 17:40:03 GMTDespite Progress in TNBC, More Biomarkers Are Needed to Improve Outcomes - MedPage TodayMedPage Today · Mon, 10 Aug 2026 15:08:50 GMTFDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer - The American Journal of Managed CareThe American Journal of Managed Care · Sun, 09 Aug 2026 16:00:00 GMTClinical Data-Matched Patient Organoids Customize Drug-Resistant TNBC Treatment - Inside Precision MedicineInside Precision Medicine · Thu, 06 Aug 2026 15:00:15 GMTDatroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy - AstraZenecaAstraZeneca · Fri, 31 Jul 2026 07:00:00 GMT